Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Status:
Completed
Trial end date:
2019-10-02
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and
tirabrutinib in adults with active Sjogren's Syndrome (SjS).